drugset
drugset / Trial / NCT05074992

A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma

NCT05074992 ↗

Phase 2 Terminated 1 enrolled University College, London Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment

Summary

The NeAT Glio trial will evaluate whether the addition of ipilimumab prior to the current standard treatment of surgery and chemoradiotherapy will improve survival in patients with newly diagnosed glioblastoma.

Timeline

Start
2022-08-24
Primary completion
2023-05-02
Completion
2023-05-02

Outcome

Outcome not reported

Stopped: “Support withdrawn from drug company supplying IMP”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody 3 mg/kg Intravenous

Indications

glioblastoma